7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Temporal and spatial concomitance of exanthema and dysesthesia in a patient with SARS-Cov-2 infection

      letter
      Brain, Behavior, & Immunity - Health
      The Author(s). Published by Elsevier Inc.
      SARS-Cov-2, COVID-19, dysesthesia, exanthema

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the editor, We’ve read with interest the article by Liguori (Liguori et al., 2020) and the answer by Krajewski (Krajewski et al., 2020) and particularly the description of dysesthesia. We would like to add to these descriptions the case of another patient with dysesthesia while adding new elements in understanding the pathophysiology of these latter. Indeed, we observed a patient who simultaneously presented dysesthesia and a viral exanthema in the same skin areas The patient is a 50-years-old male without any past medical history who presented a fever of 38.2°C and dry cough associated with myalgia. The SARS-Cov-2 infection was documented thanks to RT-PCR. On day 2 after the onset of disease, dysesthesia appeared acutely on his back, the back of both arms and the chest. Symptoms followed metameres (Proximal part of C7-C8 and from T2 to T9), were symmetrically distributed and had the same intensity in all areas. Sensations were increased by pressure and touch such as clothes, backpack, or movements of the car seat… It was particularly true during the night while moving in bed. Symptoms were calmed down by warm such as shower or sweating but only for a short period. Interestingly, a slight exanthema was present in the same areas and only where neurological symptoms were present (Fig 1 and Fig 2 ). No treatment was given. Neurological manifestations and exanthema last for five days and progressively disappeared. Curiously, anosmia and dysgeusia appeared as the other neurological manifestations disappeared. Figure 1 Exanthema present on the back Figure 1 Figure 2 Exanthema on the chest Figure 2 Apart one of the two patients reported by Krajewski (Krajewski et al., 2020) we found, in the literature, another patient who presented skin exanthema and paraesthesia (Tatu et al., 2020). However, no details about a potential link between skin eruption and neurological manifestations are given. Contrary to our case, it seems, that for the second patient described by Krajewski (Krajewski et al., 2020) neurological and skin manifestations were spatially dissociated. Exact pathophysiology of exanthema during viral infection is not clearly known but antigens-antibodies complexes are widely reported as a potential explanation (Gupta et al., 2020; Mims, 1966). Dysesthesia is the consequence of peripheral nerve damage (Asbury and Fields, 1984) and could be in part in relation to small fibers inflammation (Levine, 2018). In our case, the metameric distribution advocates for a direct effect of the virus on neurological fibres in relation with its neurotropic characteristics (Liguori et al., 2020; Zhou et al., 2020). The concomitance (temporal and spatial) of skin and neurological manifestations let us think of local inflammation due to immune reaction against virus which could have led to exanthema and part of small fibers inflammation. Other case of such manifestations could help understanding this complex disease with neurological and skin tropism, especially if skin biopsy could be performed.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

          Coronavirus disease 2019 (COVID-19), a disease caused by the novel betacoronavirus (SARS-CoV-2), has become a global pandemic threat. The potential involvement of COVID-19 in central nervous system (CNS) has attracted considerable attention due to neurological manifestations presented throughout the disease process. In addition, SARS-CoV-2 is structurally similar to SARS-CoV, and both bind to the angiotensin-converting enzyme 2 (ACE2) receptor to enter human cells. Thus, cells expressing ACE2, such as neurons and glial cells may act as targets and are thus vulnerable to SARS-CoV-2 infection. Here, we have reviewed the neurological characteristics of COVID-19 and summarized possible mechanisms of SARS-CoV-2 invasion of the CNS. COVID-19 patients have presented with a number of different neurological symptoms such as headache, dizziness, hyposmia, and hypogeusia during the course of illness. It has also been reported recently that some cases of COVID-19 have presented with concurrent acute cerebrovascular disease (acute ischemic stroke, cerebral venous sinus thrombosis, cerebral hemorrhage, subarachnoid hemorrhage), meningitis/encephalitis, acute necrotizing hemorrhagic encephalopathy, and acute Guillain–Barré syndrome. Furthermore, SARS-CoV-2 RNA detected in a cerebrospinal fluid specimen of a patient with COVID-19 have provided direct evidence to support the theory of neurotropic involvement of SARS-CoV-2. However, the underlying neurotropic mechanisms of SARS-CoV-2 are yet to be established. SARS-CoV-2 may affect CNS through two direct mechanisms (hematogenous dissemination or neuronal retrograde dissemination) or via indirect routes. The underlying mechanisms require further elucidation in the future.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

            Highlights • COVID-19 is a novel pathology due to SARS-CoV2 infection. • Nervous system manifestations of SARS-CoV2 infection has been reported. • Neurological symptoms occur in more than 90% of patients with SARS-CoV2 infection. • Women more frequently present subjective neurological symptoms than men.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning

              Small fiber neuropathy (SFN) has a poorly understood pathology, but patients would benefit from determination of clinical phenotypes that allows for better diagnosis and treatment planning. I propose that patients should be classified dependent on whether there is sodium channel dysfunction, classic neurologic symptoms only, widespread neuropathic pain, or autonomic symptoms. Patients with SFN can then be considered in light of their clinical phenotype, allowing for focus on subsets of patients who might have diagnosable conditions or be more prone to responding to a particular type of therapy that may not be efficacious in the broader patient population with SFN. There are several therapies currently available that can address the symptoms of SFN; however, to develop novel therapeutic strategies, it will be imperative to classify patients to understand and target the underlying pathology.
                Bookmark

                Author and article information

                Journal
                Brain Behav Immun Health
                Brain Behav Immun Health
                Brain, Behavior, & Immunity - Health
                The Author(s). Published by Elsevier Inc.
                2666-3546
                23 October 2020
                23 October 2020
                : 100165
                Affiliations
                [1]Infectious Diseases Department, ELSAN Polyclinique de Limoges, 18 rue du Général Catroux, 87000, Limoges, France
                Article
                S2666-3546(20)30130-7 100165
                10.1016/j.bbih.2020.100165
                7582041
                10a16efb-ef75-43d0-a1a9-e5627eec0346
                © 2020 The Author(s)

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 7 October 2020
                : 11 October 2020
                : 21 October 2020
                Categories
                Letter to the Editor

                sars-cov-2,covid-19,dysesthesia,exanthema
                sars-cov-2, covid-19, dysesthesia, exanthema

                Comments

                Comment on this article